Periods | Baseline | L-NMMA | Post infusion | P (GLM-within) |
---|---|---|---|---|
11:00 AM | 12:00 AM | 1:00 PM | ||
PRC(pg/ml) | ||||
Placebo | 8.1 ± 4.3 | 6.1 ± 3.2** | 5.9 ± 3.2** | 0.670 |
Tolvaptan | 9.9 ± 6.8 | 7.5 ± 4.6** | 7.5 ± 5.4** | |
p (GLM between) 0.305 | ||||
p (paired t-test, between) | 0.101 | 0.050 | 0.038 | Â |
P-AngII (pg/ml) | ||||
Placebo | 9.5 ± 4 | 8.6 ± 3.7 | 8.0 ± 3.3* | 0.156 |
Tolvaptan | 11.9 ± 6.2 | 9.4 ± 4.6* | 9.5 ± 5.1* | |
p (GLM between) 0.686 | ||||
p (paired t-test, between) | 0.094 | 0.403 | 0.117 | Â |
P- Aldo (pmol/L) | ||||
Placebo | 70 ± 2 | 75 ± 2 | 64 ± 2 | 0.949 |
Tolvaptan | 71 ± 2 | 78 ± 2 | 66 ± 1 | |
p (GLM between) 0.899 | ||||
p (paired t-test, between) | 0.962 | 0.785 | 0.840 | Â |
P- AVP (pg/ml) | ||||
Placebo | 0.20 ± 0.15 | 0.20 ± 0.15 | 0.20 ± 0.20 |  |
Tolvaptan | 0.70 ± 0.45 | 0.70 ± 0.55 | 0.70 ± 0.60 | |
p (Wilcoxon’s signed rank test, between) | <0.001 | <0.001 | <0.001 |